Rocuronium

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intraoperative Complications

Conditions

Intraoperative Complications, Postoperative Complications, Laparoscopy, Surgical Complications From General Anesthesia, Ventilator-Induced Lung Injury

Trial Timeline

Jan 1, 2014 → Oct 1, 2015

NCT ID

NCT02025075

About Rocuronium

Rocuronium is a pre-clinical stage product being developed by Merck for Intraoperative Complications. The current trial status is completed. This product is registered under clinical trial identifier NCT02025075. Target conditions include Intraoperative Complications, Postoperative Complications, Laparoscopy.

What happened to similar drugs?

1 of 3 similar drugs in Intraoperative Complications were approved

Approved (1) Terminated (0) Active (2)

🔄pudexacianinium chlorideAstellas PharmaPhase 3

✅FlosealBaxterApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02812186	Approved	Completed	Dec 27, 2016	Feb 6, 2019	Cholecystitis
NCT02703909	Approved	Completed	May 1, 2016	Oct 1, 2017	Morbid Obesity
NCT02553629	Approved	Completed	Sep 1, 2015	Apr 1, 2016	Surgical Conditions
NCT02320734	Approved	Completed	Feb 1, 2015	Sep 1, 2016	Neuromuscular Block
NCT02025075	Pre-clinical	Completed	Jan 1, 2014	Oct 1, 2015	Intraoperative Complications
NCT00902070	Pre-clinical	Completed	Nov 1, 2007	Oct 1, 2010	Anesthesia

Competing Products

3 competing products in Intraoperative Complications

See all competitors

Product	Company	Stage	Hype Score
pudexacianinium chloride	Astellas Pharma	Phase 3	40
pudexacianinium chloride	Astellas Pharma	Phase 3	40
Floseal	Baxter	Approved	40